These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6323421)

  • 21. Activation of normal and abnormal human factor IX with trypsin.
    Monroe DM; Noyes CM; Straight DL; Roberts HR; Griffith MJ
    Arch Biochem Biophys; 1985 May; 238(2):490-6. PubMed ID: 3873217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood clotting factor IX Niigata: substitution of alanine-390 by valine in the catalytic domain.
    Sugimoto M; Miyata T; Kawabata S; Yoshioka A; Fukui H; Takahashi H; Iwanaga S
    J Biochem; 1988 Dec; 104(6):878-80. PubMed ID: 3243764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cathepsin G, a regulator of human vitamin K, dependent clotting factors and inhibitors.
    Turkington PT
    Thromb Res; 1992 Jul; 67(2):147-55. PubMed ID: 1440518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydrophobic contact between the two epidermal growth factor-like domains of blood coagulation factor IX contributes to enzymatic activity.
    Celie PH; Lenting PJ; Mertens K
    J Biol Chem; 2000 Jan; 275(1):229-34. PubMed ID: 10617609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence against collagen activation of platelet-associated factor XI as a mechanism for initiating intrinsic clotting.
    Osterud B; Harper E; Rapaport SI; Lavine KK
    Scand J Haematol; 1979 Mar; 22(3):205-13. PubMed ID: 451451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding of factors IX and IXa to cultured vascular endothelial cells.
    Stern DM; Drillings M; Nossel HL; Hurlet-Jensen A; LaGamma KS; Owen J
    Proc Natl Acad Sci U S A; 1983 Jul; 80(13):4119-23. PubMed ID: 6602986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insertion loop 256-268 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII.
    Kolkman JA; Mertens K
    Biochemistry; 2000 Jun; 39(25):7398-405. PubMed ID: 10858287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of 125I-factor IX and 125I-factor X: effect of tissue factor and factor VII, factor Xa and thrombin.
    Osterud B; Rapaport SI
    Scand J Haematol; 1980 Mar; 24(3):213-26. PubMed ID: 7375819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa Is required for its binding to cofactor VIIIa.
    Larson PJ; Stanfield-Oakley SA; VanDusen WJ; Kasper CK; Smith KJ; Monroe DM; High KA
    J Biol Chem; 1996 Feb; 271(7):3869-76. PubMed ID: 8632006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterogeneity of factor IX BM. Difference of cleavage sites by factor XIa and Ca2+ in factor IX Kashihara, factor IX Nagoya and factor IX Niigata.
    Yoshioka A; Ohkubo Y; Nishimura T; Tanaka I; Fukui H; Ogata K; Kamiya T; Takahashi H
    Thromb Res; 1986 Jun; 42(5):595-604. PubMed ID: 3487139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of factor IX by activated factor X: a link between the extrinsic and intrinsic coagulation systems.
    Kalousek F; Konigsberg W; Nemerson Y
    FEBS Lett; 1975 Feb; 50(3):382-5. PubMed ID: 1116608
    [No Abstract]   [Full Text] [Related]  

  • 32. Inhibition of activated porcine factor IX by dansyl-glutamyl-glycyl-arginyl-chloromethylketone.
    Lollar P; Fass DN
    Arch Biochem Biophys; 1984 Sep; 233(2):438-46. PubMed ID: 6435527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of lipid binding and kinetic properties of normal, variant, and gamma-carboxyglutamic acid modified human factor IX and factor IXa.
    Jones ME; Griffith MJ; Monroe DM; Roberts HR; Lentz BR
    Biochemistry; 1985 Dec; 24(27):8064-9. PubMed ID: 3879187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood clotting factor IX Nagoya 3: the molecular defect of zymogen activation caused by an arginine-145 to histidine substitution.
    Suehiro K; Miyata T; Takeya H; Takamatsu J; Saito H; Murakawa M; Okamura T; Niho Y; Iwanaga S
    Thromb Res; 1990 Nov; 60(4):311-20. PubMed ID: 2087690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phospholipids accelerate factor IX activation by surface bound factor XIa.
    Mannhalter C; Schiffman S; Deutsch E
    Br J Haematol; 1984 Feb; 56(2):261-71. PubMed ID: 6607067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa.
    Braunstein KM; Noyes CM; Griffith MJ; Lundblad RL; Roberts HR
    J Clin Invest; 1981 Dec; 68(6):1420-6. PubMed ID: 6976355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex.
    Wu PC; Hamaguchi N; Yu YS; Shen MC; Lin SW
    Thromb Haemost; 2000 Oct; 84(4):626-34. PubMed ID: 11057861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human factor IX and factor IXa.
    Bajaj SP; Birktoft JJ
    Methods Enzymol; 1993; 222():96-128. PubMed ID: 8412817
    [No Abstract]   [Full Text] [Related]  

  • 39. Reactivity of bovine blood coagulation factor IXa beta, factor Xa beta, and factor XIa toward fluorogenic peptides containing the activation site sequences of bovine factor IX and factor X.
    Castillo MJ; Kurachi K; Nishino N; Ohkubo I; Powers JC
    Biochemistry; 1983 Mar; 22(5):1021-9. PubMed ID: 6601494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Action of neuraminidase from Clostridium perfringens of Tay-Sachs ganglioside.
    Wenger DA; Wardell S
    Physiol Chem Phys; 1972; 4(3):224-30. PubMed ID: 4376840
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.